Acusensus Limited (ASX:ACE) has disclosed a change in the director's interest of Managing Director Alexander Jannink, following the issue of 217,213 unquoted performance rights on 3 November 2026 under the Acusensus Equity Incentive Plan Rules as part of his remuneration for the 2027 financial year.

Key Points

  • 217,213 unquoted performance rights were issued to Alexander Jannink on 3 November 2026
  • The issue followed shareholder approval at the Acusensus 2026 Annual General Meeting held on 28 October 2026
  • Jannink's total unquoted performance rights holding increased from 457,928 to 675,141 following the change
  • His holding of 14,741,818 fully paid ordinary shares remained unchanged
  • The interest is held indirectly through Jannink & Associates Pty Ltd as trustee for the Jannink Family Trust

Performance Rights Issue Details

According to the Appendix 3Y filing lodged on 4 November 2026, Acusensus issued 217,213 unquoted performance rights to Alexander Jannink on 3 November 2026. The rights were issued under, and subject to, the Acusensus Equity Incentive Plan Rules as part of Jannink's remuneration as Managing Director for the 2027 financial year. No consideration was paid for the rights, and no securities were disposed of as part of the transaction. The filing states the previous notice for Jannink was dated 29 September 2026.

Indirect Interest via Jannink Family Trust

The filing discloses that Jannink's interest in the securities is held indirectly. The registered entity is Jannink & Associates Pty Ltd ACN 622 744 870, acting as trustee for the Jannink Family Trust. Alexander Jannink is identified in the filing as a director, shareholder and beneficiary of that entity. Following the change, Jannink's total holding comprises 14,741,818 fully paid ordinary shares and 675,141 unquoted performance rights, all held through this indirect structure. No change to his ordinary share holding was reported.

Shareholder Approval at 2026 Annual General Meeting

The filing states that the issue of unquoted performance rights was made following shareholder approval granted at the Acusensus 2026 Annual General Meeting, which was held on 28 October 2026. The rights were issued in accordance with the Acusensus Equity Incentive Plan Rules. The filing confirms the interests were not traded during a closed period requiring prior written clearance. Acusensus is a technology company headquartered in Melbourne, Australia, with offices across Australia, New Zealand, the United Kingdom and the United States.